ÍøºìºÚÁÏ

Skip to main content
(352) 273-8740

Jorge E Lascano, MD

Critical Care Specialist

Photo of Jorge E Lascano
(352) 273-8740 MyUFÍøºìºÚÁÏ

Research at a glance

Top areas of exploration

  • alpha 1-Antitrypsin Deficiency , 9 publications
  • Pulmonary Disease, Chronic Obstructive , 8 publications
  • alpha 1-Antitrypsin , 7 publications
  • Cystic Fibrosis , 3 publications

Research activity

44 publications

427 citations

Why is this important?

Active clinical trials

Serpentine-1

The Sponsor is developing KB408, a replication-defective, non-integrating herpes simplex virus type 1 (HSV-1)-derived vector engineered to deliver functional full-length human SERPINA1 to the airways of people with alpha-1 antitrypsin deficiency…

Investigator
Jorge E Lascano
Status
Accepting Candidates
Ages
18 Years - 70 Years
Sexes
All
KB407-02

This study will evaluate safety and tolerability of ascending doses of nebulized KB407 in adults with cystic fibrosis.

Investigator
Jorge E Lascano
Status
Accepting Candidates
Ages
18 Years - N/A
Sexes
All
ELEVAATE OLE

Phase 2 open label extension study to evaluate SAR447537 (INBRX-101) in adults with AATD emphysema

Investigator
Jorge E Lascano
Status
Accepting Candidates
Ages
18 Years - 80 Years
Sexes
All

My publications

44 publications

2017

A rare case of disseminated Sporothrix schenckii with bone marrow involvement in a patient with idiopathic CD4 lymphocytopenia.

IDCases

•

2017

Proton Pump Inhibitor Use Is Associated With an Increased Frequency of Hospitalization in Patients With Cystic Fibrosis.

Gastroenterology research

•

2017

The important role of primary care providers in the detection of alpha-1 antitrypsin deficiency.

Postgraduate medicine

•

2017

The Utility of the "Shred Sign" in the Diagnosis of Acute Respiratory Distress Syndrome Resulting from Multifocal Pneumonia.

American journal of respiratory and critical care medicine

•

2017

Therapeutics: Alpha-1 Antitrypsin Augmentation Therapy.

Methods in molecular biology (Clifton, N.J.)

•